Skip Nav Destination
OnlineFirst
Research Article June 9 2025
Defining non-small cell lung cancer tumor microenvironment changes at primary and acquired immune checkpoint inhibitor resistance using clinical and real-world data
Lang Ho Lee; Xin Xu; Thanos Mourikis; Fanying Tang; Lauren Fairchild; Lexiang Ji; Angelo L. Grauel; Joel P. Wagner; Sebastian Szpakowski; Marc R. Pelletier; Lisa Kattenhorn; Laurent Sansregret; Carlotta Costa; Claudia Bossen; Heather Burks; Anna F. Farago; Jincheng Wu
Cancer Research Communications (2025)
Research Article June 6 2025
Histone deacetylase inhibitors target DNA replication regulators and replication stress in Ewing sarcoma cells
Stacia L. Koppenhafer; Elizabeth L. Geary; Mary V. Thomas; Emma E. Croushore; Jessica A.O. Zimmerman; Jenna M. Gedminas; Dawn E. Quelle; Rebecca D. Dodd; David J. Gordon
Cancer Research Communications (2025)
Research Article June 6 2025
Protein-level analysis of differential response to chemotherapy in triple negative breast cancer identifies CYP1B1 as a biomarker for chemotherapy resistance.
Cancer Research Communications (2025)
Research Article June 6 2025
Genetic ancestry, Intrinsic Tumor Subtypes, and Breast Cancer Survival in Latin American Women
Daniela Alves da Quinta; Darío Rocha; Cristian Yáñez; Renata Binato; Sheila Coelho. Soares-Lima; Xiaosong Huang; Daiana Ganiewich; Valentina A. Zavala; Monica Sans; Alejandra Lopez-Vazquez; Jael Quintero; Olivia Valenzuela; Antonio Quintero-Ramos; Alicia Del Toro-Arreola; Mauricio Cerda; Katherine Marcelain; Susanne Crocamo; Maria Aparecida. Nagai; Dirce M. Carraro; Marcia Maria Chiquitelli. Marques; Jorge Gómez; Nora Artagaveytia; Adrian Daneri-Navarro; Bettina G. Müller; Javier Retamales; Carlos Velazquez; Elmer A. Fernández; Osvaldo L. Podhajcer; Eliana Abdelhay; Ricardo A. Verdugo; Andrea S. Llera; Laura Fejerman
Cancer Research Communications (2025)
Research Article June 4 2025
Real-World Data on Risk Factors for Emergency Department Visits to Treat Outpatient Chemotherapy Associated Toxicities
Sanja Karovic; Erik Dvergsten; Chiara Pierattini; Ana Barac; Lauren Fay; Timothy L. Cannon; Kathleen K. Harnden; Jeanny B. Aragon-Ching; Raymund S. Cuevo; Michael L. Maitland; John F. Deeken
Cancer Research Communications (2025)
Research Article June 4 2025
Cisplatin-induced APE2 overexpression disrupts MYH9 function and causes hearing loss
Qingzhu Wang; Eric E. Irons; Wanying Zhang; Fangfang Zhao; Meng-Han Chang; Esther Dai; Joelle Jeon; Hanna Hong; Rie Maeda; Minseo Kim; Kylin A. Emhoff; Mei Yin; Belinda B. Willard; Qing Y. Zheng; Richard A. Prayson; Jordan Beach; Jennifer S. Yu; Bohua Hu; Jianjun Zhao; Jianhong Lin
Cancer Research Communications (2025)
Research Article June 3 2025
High-throughput drug screening of clear cell ovarian cancer organoids reveal vulnerability to proteasome inhibitors and dinaciclib and identify AGR2 as a therapeutic target
Takuma Yoshimura; Takashi Kamatani; Aki Ookubo; Mio Takahashi; Manabu Itoh; Toshiki Ebisudani; Yohei Masugi; Tomomi Toyonaga; Junko Hamamoto; Keiko Saotome; Kensuke Sakai; Tomoko Yoshihama; Nobuko Moritoki; Shinsuke Shibata; Hiroyuki Yasuda; Toshiro Sato; Taka-Aki Sato; Daisuke Aoki; Wataru Yamagami; Tatsuhiko Tsunoda; Tatsuyuki Chiyoda
Cancer Research Communications (2025)
Research Article May 30 2025
A phase 1 safety study of evexomostat (SDX-7320) in late-stage cancer patients: an anti-angiogenic, insulin-sensitizing drug conjugate targeting MetAP2
Monica M. Mita; Alain C. Mita; Bradley J. Carver; James M. Shanahan; Benjamin A. Mayes; Pierre J. Dufour; David Browning; Alfred Anderson-Villaluz; John S. Petersen; David J. Turnquist; Peter Cornelius
Cancer Research Communications (2025)
RSS Feeds